- Neoadjuvant chemoradiotherapy (NACRT) with cisplatin and fluorouracil led to a 44% R0 resection rate in borderline resectable esophageal squamous cell carcinoma (BR-ESCC).
Why this matters
- There are limited data on treatment strategies for BR-ESCC.
- Retrospective analysis of patients who underwent NACRT with cisplatin plus fluorouracil and irradiation (40 Gy, n=50).
- Funding: None disclosed.
- 44% of patients achieved clinical curative resection (R0 group).
- The R0 group had a longer median OS:
- 2.4 vs 0.8 years;
- HR, 0.29 (P<.01>
- 27 patients underwent surgery after NACRT:
- 14 underwent 1 course of chemotherapy, and 11 (79%) achieved R0 resection;
- 13 underwent 2 courses of chemotherapy, and 11 (85%) achieved R0 resection.
- Patients with higher pre-NACRT serum squamous cell carcinoma (SCC) antigen levels (>2 ng/mL) had:
- Worse OS: 0.8 vs 2.5 years (HR, 5.4; P<.01>
- A trend toward worse relapse-free survival: 0.4 vs 1.8 years (HR, 2.43; P=.22).
- Japanese patient population.
- Retrospective design.